The SCIP platform is an innovative technology that develops modified variants of cell surface proteins in hematopoietic stem cells (HSCs). These modifications allow the cells to maintain their essential functions while resisting depletion from immunotherapies. Furthermore, the platform features paired immunotherapies that selectively target and deplete diseased cells, ensuring that the shielded healthy cells remain unharmed.

• ·Modification of cell surface proteins in HSCs for enhanced therapy resilience
• ·Selective depletion of diseased cells while protecting healthy cells
• ·Versatile applications across various medical conditions, including genetic diseases and hematologic malignancies